Redefining the EPCAM Phenotype: Deletion Architecture Determines Lynch Syndrome Cancer Risk.
- 1Ambry Genetics, Aliso Viejo, CA.
- 2Division of Clinical Cancer Genomics, City of Hope, Duarte, CA.
- 3Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA.
Abstract
Purpose
To characterize the cancer phenotype and clinical presentation across molecularly distinct EPCAM deletion subgroups and determine how the phenotype varies with MSH2 involvement.Methods
We retrospectively evaluated 662 unrelated probands undergoing hereditary cancer multigene panel testing (MGPT) with isolated EPCAM full-gene deletions (n = 22), isolated EPCAM 3' deletions (n = 96), contiguous EPCAM full-gene deletions extending into MSH2 (n = 64), contiguous EPCAM 3' deletions extending into MSH2 (n = 116), MSH2 gross deletions (n = 155), and MSH2 nonsense/frameshift (ns/fs) variants (n = 209). Lynch syndrome (LS)-associated cancer prevalence, tumor spectrum, and PREMM5 scores were compared across cohorts. Multivariable logistic regression estimated cancer-specific associations relative to a MGPT-negative reference cohort.Results
Isolated EPCAM full-gene deletions, comprising 18.6% of observed isolated EPCAM deletions, were not significantly associated with LS-associated cancers. The LS-associated cancer prevalence was 13.6% in this cohort, compared with 54.6% with isolated EPCAM 3' deletions and 64.1%-72.2% in MSH2-involving cohorts (P < .001). Relative to MGPT-negative individuals, isolated EPCAM 3' deletions were strongly associated with colorectal cancer (odds ratio [OR], 17.59; P < .001) but not endometrial cancer (OR, 0.76; P = .790). MSH2-involving cohorts demonstrated strong associations with both colorectal (ORs, 8.50-16.03; P < .001) and endometrial cancers (ORs, 17.31-30.47; P < .001).Conclusion
These findings provide new insights into the molecular and clinical heterogeneity of germline deletions involving EPCAM. Expanded detection across the full EPCAM gene and its 3' region distinguishes isolated full-gene deletions, which do not disrupt downstream MSH2 and are not associated with LS phenotypes, from isolated 3' deletions with a colorectal-predominant phenotype, and contiguous EPCAM-MSH2 deletions with an MSH2-like LS phenotype. Precise delineation of EPCAM deletion boundaries and MSH2 involvement define three clinically relevant risk groups and support more precise risk assessment, counseling, and surveillance.
Related
- Pregnane X receptor deletion induces a lean phenotype in chow-fed mice through a liver–ileum–muscle axis involving 6α-hydroxylated bile acids and Fgf15
- Negative Symptom Dimensions Link Cognitive Impairment to Global and Social Functioning in 22q11.2 Deletion Syndrome
- Med1 deletion reprograms dental epithelium into a hair-forming epidermal architecture associated with Trp63 induction.
- Phenotypic heterogeneity in pediatric pituitary stalk interruption syndrome: greater disease burden in the metabolic-onset phenotype
- GATA2 Deficiency Presenting With a WHIM‐Like Phenotype and Subsequent Development of Monosomy 7‐Associated Myelodysplastic Syndrome in an Adolescent Female: A Case Report
BibTeX
@article{kohler2026redefining,
title = {{Redefining the EPCAM Phenotype: Deletion Architecture Determines Lynch Syndrome Cancer Risk.}},
author = {Kristin Kohler and Ashley P L Marsh and Felicia Hernandez and Carolyn Horton and John Michael O Ranola and Heather Hampel and Michael J Hall},
journal = {JCO precision oncology},
year = {2026},
month = nov,
doi = {10.1200/po-26-00974},
url = {https://europepmc.org/article/MED/42970717},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Redefining the EPCAM Phenotype: Deletion Architecture Determines Lynch Syndrome Cancer Risk.
AU - Kristin Kohler
AU - Ashley P L Marsh
AU - Felicia Hernandez
AU - Carolyn Horton
AU - John Michael O Ranola
AU - Heather Hampel
AU - Michael J Hall
PY - 2026
DA - 2026/11/02
JO - JCO precision oncology
DO - 10.1200/po-26-00974
UR - https://europepmc.org/article/MED/42970717
AB - Purpose To characterize the cancer phenotype and clinical presentation across molecularly distinct EPCAM deletion subgroups and determine how the phenotype varies with MSH2 involvement.Methods We retrospectively evaluated 662 unrelated probands undergoing hereditary cancer multigene panel testing (MGPT) with isolated EPCAM full-gene deletions (n = 22), isolated EPCAM 3' deletions (n = 96), contiguous EPCAM full-gene deletions extending into MSH2 (n = 64), contiguous EPCAM 3' deletions extending into MSH2 (n = 116), MSH2 gross deletions (n = 155), and MSH2 nonsense/frameshift (ns/fs) variants (n = 209). Lynch syndrome (LS)-associated cancer prevalence, tumor spectrum, and PREMM5 scores were compared across cohorts. Multivariable logistic regression estimated cancer-specific associations relative to a MGPT-negative reference cohort.Results Isolated EPCAM full-gene deletions, comprising 18.6% of observed isolated EPCAM deletions, were not significantly associated with LS-associated cancers. The LS-associated cancer prevalence was 13.6% in this cohort, compared with 54.6% with isolated EPCAM 3' deletions and 64.1%-72.2% in MSH2-involving cohorts (P < .001). Relative to MGPT-negative individuals, isolated EPCAM 3' deletions were strongly associated with colorectal cancer (odds ratio [OR], 17.59; P < .001) but not endometrial cancer (OR, 0.76; P = .790). MSH2-involving cohorts demonstrated strong associations with both colorectal (ORs, 8.50-16.03; P < .001) and endometrial cancers (ORs, 17.31-30.47; P < .001).Conclusion These findings provide new insights into the molecular and clinical heterogeneity of germline deletions involving EPCAM. Expanded detection across the full EPCAM gene and its 3' region distinguishes isolated full-gene deletions, which do not disrupt downstream MSH2 and are not associated with LS phenotypes, from isolated 3' deletions with a colorectal-predominant phenotype, and contiguous EPCAM-MSH2 deletions with an MSH2-like LS phenotype. Precise delineation of EPCAM deletion boundaries and MSH2 involvement define three clinically relevant risk groups and support more precise risk assessment, counseling, and surveillance.
SN - 2473-4284
ER -